CN1535159A - 包含抗人精浆蛋白单链抗体/人羧钛酶a融合蛋白及前体药物的药盒 - Google Patents

包含抗人精浆蛋白单链抗体/人羧钛酶a融合蛋白及前体药物的药盒 Download PDF

Info

Publication number
CN1535159A
CN1535159A CNA018233376A CN01823337A CN1535159A CN 1535159 A CN1535159 A CN 1535159A CN A018233376 A CNA018233376 A CN A018233376A CN 01823337 A CN01823337 A CN 01823337A CN 1535159 A CN1535159 A CN 1535159A
Authority
CN
China
Prior art keywords
human
chain antibody
carboxypeptidase
fusion protein
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA018233376A
Other languages
English (en)
Other versions
CN1278739C (zh
Inventor
郝晓柯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fourth Military Medical University FMMU
Original Assignee
Fourth Military Medical University FMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fourth Military Medical University FMMU filed Critical Fourth Military Medical University FMMU
Publication of CN1535159A publication Critical patent/CN1535159A/zh
Application granted granted Critical
Publication of CN1278739C publication Critical patent/CN1278739C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明涉及抗体导向的酶－前体药物疗法(ADEPT)领域，更具体地，本发明涉及包含抗人精浆蛋白单链抗体/人羧肽酶A融合蛋白及前体药物甲氨喋呤－α－肽衍生物的药盒，该药盒适用于经ADEPT疗法治疗前列腺癌。本发明还涉及抗人精浆蛋白单链抗体/人羧肽酶A融合蛋白。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CNB018233376A 2001-06-08 2001-06-08 包含抗人精浆蛋白单链抗体/人羧肽酶a融合蛋白及前体药物的药盒 Expired - Fee Related CN1278739C (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2001/000924 WO2002100431A1 (fr) 2001-06-08 2001-06-08 Kit pharmaceutique comprenant une proteine de fusion carboxypeptidase humaine dirigee contre un anticorps a chaine simple de proteine plasmatique seminale et promedicament

Publications (2)

Publication Number Publication Date
CN1535159A true CN1535159A (zh) 2004-10-06
CN1278739C CN1278739C (zh) 2006-10-11

Family

ID=4574810

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018233376A Expired - Fee Related CN1278739C (zh) 2001-06-08 2001-06-08 包含抗人精浆蛋白单链抗体/人羧肽酶a融合蛋白及前体药物的药盒

Country Status (4)

Country Link
US (1) US20050053611A1 (zh)
EP (1) EP1459761A4 (zh)
CN (1) CN1278739C (zh)
WO (1) WO2002100431A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103156884A (zh) * 2012-04-28 2013-06-19 陕西精健新星生物医药有限公司 精浆的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
GB9517001D0 (en) * 1995-08-18 1995-10-18 Denny William Enediyne compounds
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
ATE366121T1 (de) * 1998-02-03 2007-07-15 Protiva Biotherapeutics Inc Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
US20030108544A1 (en) * 1999-09-01 2003-06-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020168737A1 (en) * 2001-01-24 2002-11-14 Cornish Virginia W. Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization
WO2002099040A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Igs as modifiers of the p53 pathway and methods of use
EP1560593B1 (en) * 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103156884A (zh) * 2012-04-28 2013-06-19 陕西精健新星生物医药有限公司 精浆的用途
CN103156884B (zh) * 2012-04-28 2015-02-04 陕西精健新星生物医药有限公司 精浆的用途

Also Published As

Publication number Publication date
EP1459761A1 (en) 2004-09-22
EP1459761A4 (en) 2005-04-13
US20050053611A1 (en) 2005-03-10
CN1278739C (zh) 2006-10-11
WO2002100431A1 (fr) 2002-12-19

Similar Documents

Publication Publication Date Title
ES2267499T3 (es) Procedimiento para la produccion de toxina difterica.
ES2386534T3 (es) Expresión heteróloga de proteínas de Neisseria
JP6243452B2 (ja) アルブミン結合アルギニンデイミナーゼ融合たんぱく質を含有する医薬組成物
CA2967077A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
JP2019502684A (ja) Ｃ末端リジンで結合体化された免疫グロブリン
US11623965B2 (en) Prodruggable antibodies, prodrugs thereof, and methods of use and making
JPH04504713A (ja) 共役ポリペプチドとその調製および使用方法
CN101143902B (zh) 抗HER2单链抗体-力达霉素强化融合蛋白HER2(Fv-LDM)
CN114106187A (zh) 一种靶向ogt的特异性鲨鱼单域抗体及其制备方法和应用
TWI763065B (zh) 重組融合蛋白及免疫原組合物
CN106928363A (zh) 一种FAP纳米抗体Nb12
CN1535159A (zh) 包含抗人精浆蛋白单链抗体/人羧钛酶a融合蛋白及前体药物的药盒
CN107236046A (zh) 一种重组人内皮抑素融合蛋白及其制备方法和应用
US8263744B2 (en) Binding proteins that bind to EpCAM linked to an effector molecule
CA2908475C (en) Use of antibody-urease conjugates for diagnostic and therapeutic purposes
CN111150844A (zh) 抗her2亲合体靶向光敏剂的合成和应用
CN106536738A (zh) 抗体基因的表达‑分泌系统
JPS60185799A (ja) ヒト癌壊死因子
EP1175227A1 (fr) Anticorps monoclonal dirige contre les cellules de carcinome renal humain
CN104119444B (zh) 抗肿瘤融合蛋白及其制备方法和用途
WO2005103088A1 (fr) Proteine hybride vh-ldp-ae renforçant des anticorps a domaine unique
CN106928368A (zh) 一种FAP纳米抗体Nb57
Miao et al. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin
CN102250252A (zh) 胃泌素释放肽导向融合蛋白
CN110527680A (zh) 一种透明质酸裂解酶及其基因与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Correction of invention patent gazette

Correction item: Denomination of Invention

Correct: Kits comprising single chain antibody of anti human seminal protein / human carboxypeptidase A fusion protein and prodrugs

False: Kits comprising single chain antibody of anti human seminal protein / human A fusion protein and carboxyl titanium enzyme prodrug

Number: 40

Volume: 20

CI02 Correction of invention patent application

Correction item: Denomination of Invention

Correct: Kits comprising single chain antibody of anti human seminal protein / human carboxypeptidase A fusion protein and prodrugs

False: Kits comprising single chain antibody of anti human seminal protein / human A fusion protein and carboxyl titanium enzyme prodrug

Number: 40

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: INVENTION NAME; FROM: ANTI-PROTEIN SINGLE-CHAIN ANTIBODY CONTAINING COUPLED SYSTEM/ CARBOXYL TITANIUM ENZYME A FUSION PROTEIN AND PRECURSOR KIT OF MEDICAMENT TO: ANTI-PROTEIN SINGLE-CHAIN ANTIBODY CONTAINING COUPLED SYSTEM/ CARBOXYPEPTIDASE A FUSION PROTEIN AND PRECURSOR KIT OF MEDICAMENT

ERR Gazette correction

Free format text: CORRECT: INVENTION NAME; FROM: ANTI-PROTEIN SINGLE-CHAIN ANTIBODY CONTAINING COUPLED SYSTEM/ CARBOXYL TITANIUM ENZYME A FUSION PROTEIN AND PRECURSOR KIT OF MEDICAMENT TO: ANTI-PROTEIN SINGLE-CHAIN ANTIBODY CONTAINING COUPLED SYSTEM/ CARBOXYPEPTIDASE A FUSION PROTEIN AND PRECURSOR KIT OF MEDICAMENT

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061011

Termination date: 20180608